Evidence map›Paper›PMID 36350424›Full record

ArticleInflammopharmacology2023

Anti-inflammatory effects of PRIMA-1

Mehrnoosh Adib, Mahdi Taghadosi, Mohammad Naghi Tahmasebi, Arash Sharafat Vaziri, Ahmadreza Jamshidi, Mahdi Mahmoudi, Elham Farhadi

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mehrnoosh AdibImmunology Department, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mahdi TaghadosiImmunology Department, Kermanshah University of Medical Sciences, Kermanshah, Iran. mtaghad@gmail.com.
Mohammad Naghi TahmasebiCenter of Orthopedic Trans-Disciplinary Applied Research, Tehran University of Medical Sciences, Tehran, Iran.
Arash Sharafat VaziriCenter of Orthopedic Trans-Disciplinary Applied Research, Tehran University of Medical Sciences, Tehran, Iran.
Ahmadreza JamshidiRheumatology Research Center, Tehran University of Medical Sciences, Shariati Hospital, Kargar Ave, PO-BOX: 1411713137, Tehran, Iran.
Mahdi MahmoudiRheumatology Research Center, Tehran University of Medical Sciences, Shariati Hospital, Kargar Ave, PO-BOX: 1411713137, Tehran, Iran.
Elham FarhadiRheumatology Research Center, Tehran University of Medical Sciences, Shariati Hospital, Kargar Ave, PO-BOX: 1411713137, Tehran, Iran. farhadie@tums.ac.ir.ORCID http://orcid.org/0000-0002-4324-2697
Shariati Hospital · IRKermanshah University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast-like synoviocytes (FLSs), the main pathological cells in rheumatoid arthritis (RA), display tumor-like phenotype, including hyper-proliferation, apoptosis resistance, and aggressive phenotype. Excessive proliferation and insufficient apoptosis of RA-FLSs can lead to hyperplastic synovial pannus tissue, excess production of inflammatory mediators, and destruction of joints. In this article, we investigate the effect of PRIMA-1

Indexed as

Arthritis, RheumatoidSynoviocytesAnti-Inflammatory AgentsCell ProliferationCells, CulturedFibroblastsHumansInterleukin-6NF-kappa BNF-KappaB Inhibitor alphaQuinuclidinesTumor Suppressor Protein p53Anti-Inflammatory AgentseprenetapoptInterleukin-6NF-kappa BNF-KappaB Inhibitor alphaQuinuclidinesTumor Suppressor Protein p53Fibroblast-like synoviocytesNF-κBNoxaP53PRIMA-1METRheumatoid arthritis

Identifiers

PMID36350424
OpenAlexW4308640032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.